Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling

被引:34
|
作者
Park, Keun Ha [1 ]
Gu, Dong Ryun [1 ,2 ]
Jin, Su Hyun [2 ]
Yoon, Chi-Su [3 ,4 ]
Ko, Wonmin [3 ,4 ]
Kim, Youn Chul [3 ,4 ]
Lee, Seoung Hoon [1 ,2 ,5 ]
机构
[1] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea
[2] Wonkwang Univ, CMFR, Sch Med, Iksan 54538, Jeonbuk, South Korea
[3] Wonkwang Univ, Inst Pharmaceut Res & Dev, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[4] Wonkwang Univ, Standardized Mat Bank New Bot Drugs, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Biomat & Implant, Iksan 54538, Jeonbuk, South Korea
来源
AMERICAN JOURNAL OF CHINESE MEDICINE | 2017年 / 45卷 / 08期
关键词
Pueraria lobate; Puerariae radix; Osteoclast; NFATc1; PGC1; beta; CREB; Bone Disease; PREVENTS BONE LOSS; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIALS; OVARIECTOMIZED MICE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR; SOY ISOFLAVONES; IN-VITRO; PHYTOESTROGENS;
D O I
10.1142/S0192415X17500938
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-kappa B ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC1 beta), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-beta estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
引用
收藏
页码:1725 / 1744
页数:20
相关论文
共 50 条
  • [1] Kaempferol Inhibits IL-1β-Stimulated, RANKL-mediated Osteoclastogenesis via Downregulation of MAPKs, c-Fos, and NFATc1
    Lee, Won-Seok
    Lee, Eun-Gyeong
    Sung, Myung-Soon
    Yoo, Wan-Hee
    INFLAMMATION, 2014, 37 (04) : 1221 - 1230
  • [2] Cytosolic malate dehydrogenase regulates RANKL-mediated osteoclastogenesis via AMPK/c-Fos/NFATc1 signaling
    Oh, Se Jeong
    Gu, Dong Ryun
    Jin, Su Hyun
    Park, Keun Ha
    Lee, Seoung Hoon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 475 (01) : 125 - 132
  • [3] Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis
    Kim, Ju-Young
    Cheon, Yoon-Hee
    Yoon, Kwon-Ha
    Lee, Myeung Su
    Oh, Jaemin
    BMB REPORTS, 2014, 47 (08) : 451 - 456
  • [4] CA-074Me compound inhibits osteoclastogenesis via suppression of the NFATc1 and c-FOS signaling pathways
    Patel, Neel
    Nizami, Saqib
    Song, Lee
    Mikami, Maya
    Hsu, Anny
    Hickernell, Thomas
    Chandhanayingyong, Chandhanarat
    Rho, Shim
    Compton, Jocelyn T.
    Caldwell, Jon-Michael
    Kaiser, Philip B.
    Bai, Hanying
    Lee, Heon Goo
    Fischer, Charla R.
    Lee, Francis Y.
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2015, 33 (10) : 1474 - 1486
  • [5] Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
    Hong, Guoju
    Zhou, Lin
    Han, Xiaorui
    Sun, Ping
    Chen, Zhenqiu
    He, Wei
    Tickner, Jennifer
    Chen, Leilei
    Shi, Xuguang
    Xu, Jiake
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [6] BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
    Zhang, Yufeng
    Yang, Min
    Zhang, Sheng
    Yang, Zhiqiang
    Zhu, Yufan
    Wang, Yi
    Chen, Zhe
    Lv, Xuan
    Huang, Zan
    Xie, Yuanlong
    Cai, Lin
    CELL AND BIOSCIENCE, 2022, 12 (01)
  • [7] Pyrroloquinoline Quinine Inhibits RANKL-Mediated Expression of NFATc1 in Part via Suppression of c-Fos in Mouse Bone Marrow Cells and Inhibits Wear Particle-Induced Osteolysis in Mice
    Kong, Lingbo
    Yang, Chongfei
    Yu, Lifeng
    Smith, Wanli
    Zhu, Shu
    Zhu, Jinyu
    Zhu, Qingsheng
    PLOS ONE, 2013, 8 (04):
  • [8] Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-κB and the downstream c-Fos/NFATc1 signaling pathways
    Guo, Di
    Hong, Dun
    Wang, Peng
    Wang, Jiacheng
    Chen, Lihua
    Zhao, Weibo
    Zhang, Liwei
    Yao, Can
    Chu, Binxiang
    Chen, Shenao
    Li, Zhiyan
    Chen, Haixiao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 848 : 96 - 104
  • [9] Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the NFATc1, c-Fos, and MAPK pathways
    Lee, Sung-Hoon
    Park, Shin-Young
    Kim, Jung Ha
    Kim, Nacksung
    Lee, Junwon
    BMB REPORTS, 2023, 56 (10) : 551 - 556
  • [10] BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
    Yufeng Zhang
    Min Yang
    Sheng Zhang
    Zhiqiang Yang
    Yufan Zhu
    Yi Wang
    Zhe Chen
    Xuan Lv
    Zan Huang
    Yuanlong Xie
    Lin Cai
    Cell & Bioscience, 12